Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION-PanTumor01 study.
Aaron Lisberg(APLA Health), Takahiro Kogawa(The Cancer Institute Hospital), Manali Bhave(Northwestern University), Hayato Sakaki(Tokyo University of Science), Alexander I. Spira(Virginia Cancer Specialists), Takahiro Kojima(Aichi Cancer Center), Alexandra Drakaki(University of California, Los Angeles), Rebecca S. Heist(Massachusetts General Hospital), Manabu Kato(Aichi Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Mohamad A. Salkeni(Virginia Cancer Specialists), Xīn Gào(Qingdao University), Omar Alhalabi(The University of Texas MD Anderson Cancer Center), G. Klauss(Daiichi Sankyo (United States)), Yasuyuki Kakurai(Daiichi-Sankyo (Japan))
Cited by 15
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k